Clinical Trial Update: Biodentine Versus White MTA Pulpotomy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Biodentine to White MTA for pulpotomy in extensive decay of primary molars has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive Decay in Primary Molars

Drugs mentioned

• Biodentine (tricalcium silicate cement)
• White MTA (mineral trioxide aggregate)

Snippet

Sponsor: University Ghent | Conditions: Extensive Decay in Primary Molars | Phase 3 | Status: COMPLETED